BIOMAT Database Logo BIOMAT Database Logo

Predicting nonresponsiveness to depression treatments. 1996

N F Feiner

UI MeSH Term Description Entries
D011336 Probability The study of chance processes or the relative frequency characterizing a chance process. Probabilities
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D005473 Fluoxetine The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. Fluoxetin,Fluoxetine Hydrochloride,Lilly-110140,N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine,Prozac,Sarafem,Lilly 110140,Lilly110140
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

N F Feiner
Immunologic nonresponsiveness to tumors.
January 1998, Critical reviews in oncogenesis,
N F Feiner
Elevated plasma thymopoietin associated with therapeutic nonresponsiveness in major depression.
July 2000, Biological psychiatry,
N F Feiner
Nonresponsiveness of patients to token economies.
November 1972, Behaviour research and therapy,
N F Feiner
Comparing depression treatments.
June 2003, The American journal of psychiatry,
N F Feiner
Depression, III: treatments.
January 2003, The American journal of psychiatry,
N F Feiner
Treatments in depression.
January 2006, Dialogues in clinical neuroscience,
N F Feiner
Predicting Depression.
August 2019, The American journal of psychiatry,
N F Feiner
Predicting onset of depression: the Vulnerability to Depression Questionnaire.
November 2001, The British journal of clinical psychology,
N F Feiner
[Application of fragrances to treatments for depression].
February 1995, Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology,
N F Feiner
Traditional Chinese Medicine in treatments to depression.
March 2009, Neuro endocrinology letters,
Copied contents to your clipboard!